Ecolab, Inc. engages in the provision of products and services in the field of water, hygiene, and energy. It operates through the following segments: Global Industrial, Global Institutional & Specialty, Global Energy & Life Science, and Other. The Global Industrial segment consists of the water, food and beverage, paper, and downstream operating segments. It offers water treatment and process applications, and cleaning and sanitizing solutions to industrial customers within the manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, pulp and paper, commercial laundry, global petroleum, and petrochemical industries. The Global Institutional & Specialty segment consists of the institutional, specialty and healthcare operating segments. It provides cleaning and sanitizing products to the foodservice, hospitality, lodging, healthcare, government, education, and retail industries. The Global Healthcare & Life Sciences segment includes the healthcare and life sciences operations. It provides cleaning and sanitizing products to the healthcare, personal care, and pharmaceutical industries. The Other segment includes Pest Elimination operations, which provide services to detect, eliminate and prevent pests, such as rodents and insects, CTG operations, which produce and sell colloidal silica, which is comprised of nano-sized particles of silica in water used for binding and polishing applications, and Textile Care operations, which provide products and services that manage the entire wash process through custom designed programs, premium products, dispensing equipment, water and energy management and reduction, and real time data management. The company was founded by Merritt J. Osborn in 1923 and is headquartered in St. Paul, MN.

3M Innovative Properties Co. acquires and manages intellectual property right. It engages in the acquisition and ownership of the intellectual property rights to the products designed and manufactured by its parent company 3M Corporation. The company was founded on May 10, 1999 and is headquartered in Roseville, MN.

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates through three segments: BioScience, Medication Delivery, and Renal. - The BioScience segment manufactures recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products and technologies used in adult stem-cell therapies; and vaccines. - The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs, intravenous nutrition products; infusion pumps; and inhalation anesthetics. This segment also offers products and services related to pharmacy compounding, drug formulation, and packaging technologies. - The Renal segment provides products to treat end-stage renal disease and irreversible kidney failure. This segment also offers solutions and other products for peritoneal dialysis, a home-based therapy and product for hemodialysis, which is conducted in a hospital or clinic. Baxter International Inc. has collaborations with HHD LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. for the development of a home hemodialysis machine. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and patients at home under physician supervision. The company was founded in 1931 and is headquartered in Deerfield, Illinois.

Part of University of Arkansas System, Board of Trustees of The University of Arkansas is a company headquartered in Fayetteville, AR, that owns and operates radio stations.

Omya International AG is a Swiss private company located in Oftringen, with operations in Malaysia and Austria, that manufactures industrial minerals. It was founded in 1884 by Gottfried Plüss-Staufer. Herlinde Wauteraerts is currently the CEO of the firm.\nThe company says this about itself: Omya is a leading global producer of industrial minerals – mainly derived from calcium carbonate, dolomite and perlite – and a worldwide distributor of specialty chemicals. The company provides a wealth of innovative product solutions that contribute to its customers' competitiveness and productivity in multiple industries such as Construction, Paper & Board, Polymers, Food and Personal & Home Care. Omya further provides Environmental Solutions targeting the agriculture, water and energy markets.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Baxter Healthcare SA engages in the development, production, and sale of healthcare systems and products. It also acquires and manages participations in pharmaceutical-chemical firms. The company was founded on December 7, 2000 and is headquartered in Glattpark, Switzerland.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Nitto Denko Corp. engages in the manufacture and sale of adhesives, optical films, semiconductors, electronic devices, and consumer products. It operates through the following segments: Industrial Tape, Optronics, Human Life, and Others. The Industrial Tape segment deals with the manufacture and sale of sealing, protective, process, and automotive materials. The Optronics segment offers optical films, printed circuits, and high-precision substrates. The Human Life segment handles the manufacturing services for nucleic acids, nucleic acid synthesis materials, and medical-related materials. The Others segment includes new businesses. The company was founded on October 25, 1918 and is headquartered in Osaka, Japan.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

STERIS, Inc., a subsidiary of STERIS Plc (Ireland), is a company headquartered in the United States specializing in orthopedic, prosthetic, and surgical appliances and supplies.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, training and youth pants, swim pants, baby wipes, feminine and incontinence care products, and other related products. The Consumer Tissue segment produces and sells facial and bathroom tissue, paper towels, napkins, and related products for household use. The K-C Professional segment supplies workplace supporting products such as wipers, tissue, towels, apparel, soaps, and sanitizers. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Arch Chemicals, Inc., is a global specialty chemical company based in Norwalk, Connecticut, involved in two main business segments: treatment products and performance products. Treatment products include chemicals to sanitize drinking water and swimming pools; industrial biocides, used to inhibit the growth of microorganisms in metal working fluids, paint, and other coatings; industrial wood preservatives and fire retardants; stains and lacquers to coat wood; and active ingredients and preservatives used in shampoos, cosmetics, and other personal care products. Arch's performance products include polyols used to make adhesives, sealants, and coatings; glycols for making antifreeze, cleaning products, and consumer goods; and hydrazine hydrate, used to make drugs, treat water, and blowing agents that strengthen plastics and rubbers by expanding them. In 2004 Arch sold off most of its microelectronic materials business segment, which provided slurry used by semiconductor manufacturers to remove and polish surfaces. In addition to 16 U.S. locations, Arch maintains operations in 20 other countries around the world. A spinoff of the Olin Corporation in 1999, Arch is a public company listed on the New York Stock Exchange.

Innovotech solves client biofilm problems through its Biofilm Contract Research Department. The company has a distinguished track record of both standardized and customized research to meet client needs. The scope of research is from early stage identification of problems and screening of agents for "anti-biofilm activity", to research acceptable to regulatory agencies for product claim validation, to post-market product comparisons for marketing purposes. The company regularly develops in vitro models of the client specific situation as a starting point that enables any number of test parameters to be tested. Most of Innovotech's R&D has grown out of work with the MBEC™ and BEST™ assays. From these platforms, Innovotech has developed a number of unique methods for testing antimicrobial agents in solution and coated onto a large variety of surfaces that can appear in medical, dental, agricultural or industrial settings. Innovotech also combines the use of these basic platforms with internal expertise in diverse areas such as biofilms, medical devices and silver chemistry, to develop its own lines of anti-biofilm agents for various applications. The InnovoSIL™ family shows promise for use in medical devices, and Agress® has demonstrated effectiveness when tested for agricultural applications.

Silver Bullet Water Treatment Co. LLC develops water treatment systems. The firm's products include agricultural, cooling tower, and industrial systems. It also offers photochemical water treatment system that controls microorganisms and scale formation without the use of toxic chemicals. The company was founded by David Kolstad and Robert I. Hanfling in 2008 and is headquartered in Golden, CO.

Alcon Research Ltd., a subsidiary of Nestl�� SA, is a company headquartered in Huntington, WV, that manufactures optical goods.

Gladskin contains billions of bacteria, of which the vast majority protects our skin. To maintain a healthy skin environment, it is necessary to maintain a good bacterial balance. The disruption of this balance can result in, or aggravate, skin conditions. Traditional skin products and antibiotics do not differentiate between good and bad bacteria, and therefore also remove the beneficial bacteria that protect us. Gladskin contains Staphefekt.

Becton Dickinson France SAS manufactures and sells medical devices and instruments such as needles, syringes, vaccines and related products. Its products include Prefillable syringe, Safety and shielding, and Self-injection systems. The company is headquartered in Le Pont de Claix, France.

Hill's Pet Nutrition, Inc. provides pet food products and pet care services. It offers products to the breeders, veterinarians, and pet supply retailers. The company was founded by Mark L. Morris in 1939 and is headquartered in Topeka, KS.